Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
about
One small step for a yeast--microevolution within macrophages renders Candida glabrata hypervirulent due to a single point mutationPropargyl-Linked Antifolates are Dual Inhibitors of Candida albicans and Candida glabrataSystematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genesEpidemiology of invasive candidiasis: a persistent public health problemEfflux in fungi: la pièce de résistanceMultilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrataThe effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients.Local silencing controls the oxidative stress response and the multidrug resistance in Candida glabrata.Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingAzole resistance of Candida glabrata in a case of recurrent fungemiaComparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agentsChanges in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.Potassium Uptake Mediated by Trk1 Is Crucial for Candida glabrata Growth and Fitness.The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy.Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.Efflux-mediated antifungal drug resistance.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Voriconazole in clinical practice.Mechanisms of Antifungal Drug Resistance.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Fatal Case of Candidemia due to Candida glabrata.In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on Candida spp.Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.Emergence of resistance to amphotericin B and triazoles in Candida glabrata vaginal isolates in a case of recurrent vaginitis.Genotypic, phenotypic, and proteomic characterization of Candida glabrata during sequential fluconazole exposure.Typing of Candida isolates from patients with invasive infection and concomitant colonization.
P2860
Q27322886-39042155-DDC1-4916-9F49-E4A3476E96BBQ27681900-65C83523-F415-4306-8D4E-D52FAD3FD44BQ28539874-183B8466-FA57-47C2-AEFE-6ACF76435317Q29616758-2A53F015-D67D-47DB-A4BD-4E87230B03C3Q33474798-3C3A4FDD-B29F-404B-B193-B3FC138100CCQ33622915-A4877136-8ED8-4BAE-92C5-60F8539A52EDQ33847058-81BEA982-F3E7-495A-AE33-30366D15958CQ33887429-3CD2FDB3-6CDD-40A7-B073-DC25C7A02FB5Q34036604-3D14984B-F840-40EE-9321-88365DD7695FQ34430768-BA1015E3-F34D-4F00-A857-1552C9990AB6Q34509765-086AFF88-1F9A-45DE-BD7E-DE4165F3FE59Q34647337-3CF63FD7-2051-4444-A4A9-26CE650F9502Q35073016-FB202DF9-79E7-4A3D-A8D0-F24233574CC1Q35690629-7CAE38C0-1A32-4AF0-9DA6-72AE5DA20732Q35947465-92C776AD-071B-4924-AB1F-B9FB144B5765Q35983736-C322D4AE-73AA-49AB-8933-205F93131DACQ36210497-521EB8EB-30C3-4629-86A5-BC59320D4B14Q36439061-A4768E2A-14D0-42A1-9768-6FAEFDCF9188Q36825717-280532BE-8E0D-4DBA-861E-633837EF8109Q37156645-4BC96FA3-078E-4484-8A3D-1E6700C284FCQ37374850-57B11EEB-4020-48D9-BE33-DCDF8BF97269Q37608276-F738FF3E-158A-445C-B967-8F8141B4E09FQ38061736-CB922CB0-5883-42B4-8C45-67311CF14D92Q38266675-948978A1-170A-4F6E-A56F-C7A9FE45C256Q38284461-D03D4520-BEDC-4F21-A64D-B97EE9364267Q38557102-16BE94C0-0488-404D-9CE7-3FA15383B143Q41559415-310291C2-B1EB-4C0A-BD4C-A7D56B52E055Q42078949-DE4011F4-4B22-42A8-8F52-C7EC9326EE34Q42408609-613476CA-0BE4-4F45-B68D-F848F44FEB85Q43701370-DBF3A280-4DB1-4E41-BDC8-0C86FB139719Q46393306-B9D0A8A3-F053-4829-9CB1-9E09CD7572A9Q46448488-E8BFEB09-2A7B-4685-A9DF-7B37EDB3C7E3Q54375674-93B2BA8D-333A-4B2A-8B46-8CA3AC3BAA80Q54455180-9E3BB491-C750-4A8A-9C6E-0C8ABFB27DAB
P2860
Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Rapid acquisition of stable az ...... l introduction of fluconazole.
@ast
Rapid acquisition of stable az ...... l introduction of fluconazole.
@en
type
label
Rapid acquisition of stable az ...... l introduction of fluconazole.
@ast
Rapid acquisition of stable az ...... l introduction of fluconazole.
@en
prefLabel
Rapid acquisition of stable az ...... l introduction of fluconazole.
@ast
Rapid acquisition of stable az ...... l introduction of fluconazole.
@en
P2093
P2860
P1476
Rapid acquisition of stable az ...... l introduction of fluconazole.
@en
P2093
Annemarie Borst
Beth A Arthington-Skaggs
Christine J Morrison
David W Warnock
Maria T Raimer
P2860
P304
P356
10.1128/AAC.49.2.783-787.2005
P407
P577
2005-02-01T00:00:00Z